Retatrutide, developed by Soma Chems , is attracting increasing attention as a potential therapy for metabolic management . This innovative drug merges the properties of a GLP-1 receptor stimulant and a GIP receptor stimulant, aiming to not only promote metabolic improvements but also target underlying metabolic factors. Early human studies have… Read More